High-throughput functional screening using CRISPR/Cas9 system

Gancheng Wang, MingMa, Yanzhen Ye, Jianzhong Xi

doi:10.16288/j.yczz.15-329

[an error occurred while processing this directive]

Hereditas(Beijing) >

2016 , Vol. 38 >Issue 5: 391 - 401

DOI: https://doi.org/10.16288/j.yczz.15-329

Reviews

High-throughput functional screening using CRISPR/Cas9 system

Expand

1. Department of Biomedicine, College of Engineering, Peking University, Beijing 100871, China;
2. State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Molecular Medicine, Peking University, Beijing 100871, China;
3. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100871, China

Received date: 2015-10-25

Revised date: 2016-01-21

Online published: 2016-02-24

Fold

Abstract

High-throughput screening, a powerful tool for the discovery of functionally important genes responsible for certain phenotypes, is performed according to loss-of-function or gain-of-function strategies. RNAi technology or knockout approaches have been widely used in high throughput screening due to their advantages of ease use, low cost and so on. However, imcomplete knockdown activity and off-target effect hindered their utility. More recently, CRISPR/Cas9 technology is becoming a robust tool for genome editing in diverse cells or animals, since it could generate a gene mutation in a target-specific manner. In this review, we first summarize the characterization of CRISPR/Cas9 and make comparison with traditional genetic tools, then describe recent achievements of genetic screen in several model organisms using CRISPR/Cas9, finally discuss on its future challenges and opportunities.

Key words： CRISPR/Cas9; genome editing technology; high-throughput; genetic screening

Cite this article

Gancheng Wang, MingMa, Yanzhen Ye, Jianzhong Xi . High-throughput functional screening using CRISPR/Cas9 system[J]. Hereditas(Beijing), 2016 , 38(5) : 391 -401 . DOI: 10.16288/j.yczz.15-329

References

[1] Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli , and identification of the gene product. J Bacteriol , 1987, 169(12): 5429-5433.
[2] Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science , 2007, 315(5819): 1709-1712.
[3] Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, Hsu PD, Wu XB, Jiang WY, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science , 2013, 339(6121): 819-823.
[4] Mali P, Yang LH, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science , 2013, 339(6121): 823-826.
[5] Li J, Zhang Y, Chen KL, Shan QW, Wang YP, Liang Z, Gao CX. CRISPR/Cas: a novel way of RNA-guided genome editing. Hereditas (Beijing) , 2013, 35(11): 1265-1273. 李君, 张毅, 陈坤玲, 单奇伟, 王延鹏, 梁振, 高彩霞. CRISPR/Cas系统: RNA靶向的基因组定向编辑新技术. 遗传, 2013, 35(11): 1265-1273.
[6] Ohrt T, Merkle D, Birkenfeld K, Echeverri CJ, Schwille P. In situ fluorescence analysis demonstrates active siRNA exclusion from the nucleus by Exportin 5. Nucleic Acids Res , 2006, 34(5): 1369-1380.
[7] Hartenian E, Doench JG. Genetic screens and functional genomics using CRISPR/Cas9 technology. FEBS J , 2015, 282(8): 1383-1393.
[8] Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet , 2015, 16(5): 299-311.
[9] Xi JZ, Ma M, Wang GC, Luo YF. Development and perspective of high-throughput siRNA screening technology. Chin Bull Life Sci , 2014, 26(3): 276-286. 席建忠, 马明, 王干诚, 骆宇峰. 高通量siRNA筛选技术发展与展望. 生命科学, 2014, 26(3): 276-286.
[10] Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC, Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey-Prévôt B, Root DE, Sabatini DM, Taipale J, Perrimon N, Bernards R. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods , 2006, 3(10): 777-779.
[11] Westbrook TF, Martin ES, Schlabach MR, Leng YM, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, DePinho RA, Chin L, Elledge SJ. A genetic screen for candidate tumor suppressors identifies REST. Cell , 2005, 121(6): 837-848.
[12] Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang XP, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C, Barbie DA, Awad T, Zhou X, Nguyen T, Piqani B, Li C, Golub TR, Meyerson M, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA , 2008, 105(51): 20380-20385.
[13] Zhou YX, Zhu SY, Cai CZ, Yuan PF, Li CM, Huang YY, Wei WS. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature , 2014, 509(7501): 487-491.
[14] Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science , 2014, 343(6166): 80-84.
[15] Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science , 2014, 343(6166): 84-87.
[16] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature , 2002, 417(6892):

Options

Outlines

〈

〉

www.chinagene.cn
备案号：京ICP备09063187号

模态框（Modal）标题

Abstract

Cite this article

References